MetaVia’s (MTVA) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of MetaVia (NASDAQ:MTVAFree Report) in a research report released on Friday,Benzinga reports. HC Wainwright currently has a $12.00 price objective on the stock. HC Wainwright also issued estimates for MetaVia’s FY2029 earnings at ($5.01) EPS.

MetaVia Stock Performance

MetaVia stock opened at $1.55 on Friday. The business’s 50 day moving average price is $1.70. MetaVia has a fifty-two week low of $1.29 and a fifty-two week high of $5.30.

About MetaVia

(Get Free Report)

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.

See Also

Receive News & Ratings for MetaVia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MetaVia and related companies with MarketBeat.com's FREE daily email newsletter.